What factors should be considered when sequencing therapy in R/R follicular lymphoma?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, about what factors should be considered when sequencing therapy in relapsed/refractory (R/R) follicular lymphoma.

Salles highlights the different elements to consider when sequencing therapy in R/R follicular lymphoma, which includes realizing new biopsies to rule out histological transformations, evaluating the treatment options, and considering the toxicities accompanying different therapies.